Robert J. Kreitman

Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic <i>BRAF</i> V600–Mutant Anaplastic Thyroid Cancer

Vivek Subbiah, Robert J. Kreitman, Zev A. Wainberg et al. · Journal of Clinical Oncology · 2017 · 885 citations · Full text

Medicine, Oncology, Pharmacology +17

Efficacy of the Anti-CD22 Recombinant Immunotoxin BL22 in Chemotherapy-Resistant Hairy-Cell Leukemia

Robert J. Kreitman, Wyndham H. Wilson, Karen Bergeron et al. · New England Journal of Medicine · 2001 · 511 citations · Full text

Medicine, Oncology, Pharmacology +11

Phase I Trial of Recombinant Immunotoxin Anti-Tac(Fv)-PE38 (LMB-2) in Patients With Hematologic Malignancies

Robert J. Kreitman, Wyndham H. Wilson, Jeffrey D. White et al. · Journal of Clinical Oncology · 2000 · 421 citations

Medicine, Oncology, Pharmacology +15

Phase I Study of SS1P, a Recombinant Anti-Mesothelin Immunotoxin Given as a Bolus I.V. Infusion to Patients with Mesothelin-Expressing Mesothelioma, Ovarian, and Pancreatic Cancers

Raffit Hassan, Susie Bullock, Ahalya Premkumar et al. · Clinical Cancer Research · 2007 · 381 citations · Full text

Pharmacy, Oncology, Pharmacology +16

Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study

Vivek Subbiah, Robert J. Kreitman, Zev A. Wainberg et al. · Annals of Oncology · 2022 · 346 citations · Full text

Medicine, Oncology, Pharmacotherapy +13